Nektar Therapeutics
NASDAQ:NKTRBiotechnology
-$1.24 today
- Market cap
- $987.44M
- Beta
- 1.15
- P/E (TTM)
- -9.3
- EPS (TTM)
- -$6.39
Volume 0.71M
Average 1.00M
NKTR Purchases of Investments
Cash used to buy marketable securities and other investments.
Nektar TherapeuticsNASDAQ: NKTR
Purchases of Investments · Q2 FY2026 · quarter ended Jun 2026
Purchases of investments growth accelerates
Q2 FY2026 purchases of investments of $535.45M (cash outflow) rose 2729.9% year over year, ahead of the +830.6% change in trailing-twelve-month purchases of investments. Sequentially, it rose 18.4% from the prior quarter. Over 3 fiscal years it compounded at -15.2% a year.
Context
- Purchases of investments amounted to 516.0% of revenue in FY2025, up 250.1 pp from a year earlier.
- Purchases of investments grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +2729.9% holds above the trailing-twelve-month pace of +830.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Purchases of Investments history
USD · from the cash flow
- Latest · FY2025
- (285.01M) USD
- Year-over-year change
- -8.9%
| Period | Period end | Purchases of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (285.01M) | -8.9% |
| FY2024 | 2024-12-31 | (261.71M) | +48.9% |
| FY2023 | 2023-12-31 | (511.7M) | -9.4% |
| FY2022 | 2022-12-31 | (467.91M) | +51.3% |
| FY2021 | 2021-12-31 | (960.69M) | — |
Purchases of Investments vs competitors
How NKTR compares with its peers on the latest reported figures
- Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +830.6% is the highest of 7, against a peer median of -34.6%.
- Purchases of investments amounts to 2251.1% of revenue for NKTR, versus a peer median of 128.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.23B USD | +830.6% | -15.2% | 2251.1% | |
| LTM Jun 2026 | $894M USD | -7.3% | -4.6% | 764.1% | |
| LTM Mar 2026 | $245.78M USD | +235.8% | +11.5% | — | |
| LTM Mar 2026 | $202.4M USD | +485.0% | +20.0% | 128.9% | |
| LTM Jun 2026 | $194.76M USD | -62.0% | -8.3% | 185.5% | |
| LTM Mar 2026 | €149.18M EUR | -64.3% | +14.5% | 400.0% | |
| LTM Mar 2026 | $110.23M USD | — | -6.6% | 235.1% | |
| LTM Mar 2026 | $30M USD | -91.4% | — | 7.8% | |
| LTM Jun 2024 | $0 USD | — | -29.7% | 0.0% | |
| LTM Dec 2025 | $0 USD | — | +7.7% | 0.0% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding NKTR) | — | -34.6% | +1.5% | 128.9% | |
Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (523.84M) | (368.2M) | (276.06M) | (118.96M) | (164.08M) |
| Depreciation & Amortization | 14.15M | 13.03M | 7.82M | 4.39M | (4.49M) |
| Deferred Income Tax | 8.02M | 2.71M | (140K) | 0 | 0 |
| Stock-Based Compensation | 94.67M | 57.32M | 33.39M | 21.61M | 12.65M |
| Change in Working Capital | (23.08M) | 492K | (19.8M) | (6.24M) | (37.02M) |
| Accounts Receivables | 12.4M | 16.51M | 4.78M | (3.05M) | 0 |
| Inventory | (509K) | (3.4M) | 699K | 497K | 0 |
| Accounts Payables | (11.69M) | 3.1M | (2.88M) | 2.67M | (625K) |
| Other Working Capital | (23.27M) | (15.72M) | (22.39M) | (6.36M) | (36.39M) |
| Other Non-Cash Items | 17.41M | (9.36M) | 62.19M | (76.51M) | (15.58M) |
| Operating Cash Flow | (412.66M) | (304.01M) | (192.61M) | (175.71M) | (208.51M) |
| Capital Expenditures | (14.99M) | (5.68M) | (865K) | (1.47M) | (171K) |
| Acquisitions (Net) | (217.77M) | 13.2M | 0 | 65.39M | (697K) |
| Purchases of Investments | (960.69M) | (467.91M) | (511.7M) | (261.71M) | (285.01M) |
| Sales of Investments | 1.18B | 826.23M | 650.88M | 340.36M | 284.68M |
| Other Investing Activities | 217.77M | 0 | 1.25M | 0 | 0 |
| Investing Cash Flow | 202.78M | 365.84M | 139.56M | 142.57M | (1.2M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.24M | 758K | 30K | 30.12M | 180.57M |
| Common Stock Repurchased | 0 | 0 | 0 | (3M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3M | 750K | 0 | 15M | 0 |
| Financing Cash Flow | 36.24M | 1.51M | 30K | 42.12M | 180.57M |
| Effect of Forex Changes | (92K) | (327K) | 62K | (4K) | 6K |
| Net Change in Cash | (173.74M) | 63.01M | (52.95M) | 8.98M | (29.14M) |
| Free Cash Flow | (427.65M) | (309.68M) | (193.47M) | (177.18M) | (208.68M) |
Nektar Therapeutics
NASDAQ:NKTR
Intrinsic Alpha fair value
Locked
Current Price
$34.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.